Results and conclusions
Twenty-two (29%) patients had primary mitral regurgitation (MR). During
follow-up, 5 patients died due to CV events, 8 were hospitalized for HF.
On univariate Cox regression analysis, CV events were associated with
eGFR (HR; 0.960, 95% CI; 0.926–0.995, p = 0.027), tricuspid annular
plane systolic excursion (TAPSE, HR; 0.874, 95% CI; 0.789–0.968, p =
0.010), and significant residual MR (HR; 11.652, 95% CI; 3.257–41.691,
p <0.001). On multivariate Cox regression analysis, TAPSE (HR;
0.788, 95% CI; 0.788–0.987, p = 0.029) and significant residual MR
(HR; 9.373, 95% CI; 2.581–34.033, p = 0.001) were independently
associated with CV events. TAPSE
<11 mm was the best cut-off criteria for predicting CV events.
RV function was independently associated with clinical outcomes
following MitraClip therapy. TAPSE is a simple parameter for predicting
CV events in patients with MR who are undergoing MitraClip therapy.